Review
Published on 17 Sep 2020
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.554313
- 25,786 views
- 50 citations
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,750 articles
Original Research
Published on 16 Sep 2020
Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.544789
- 3,150 views
- 11 citations
Original Research
Published on 16 Sep 2020
Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01777
- 15,710 views
- 30 citations
Original Research
Published on 15 Sep 2020
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.561598
- 11,806 views
- 78 citations
Original Research
Published on 15 Sep 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01568
- 7,310 views
- 2 citations
Original Research
Published on 15 Sep 2020
Integrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.554759
- 26,910 views
- 188 citations
Review
Published on 09 Sep 2020
The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01742
- 7,984 views
- 17 citations
Case Report
Published on 08 Sep 2020
Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01635
- 3,409 views
- 3 citations
Systematic Review
Published on 08 Sep 2020
The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01636
- 4,666 views
- 16 citations
Original Research
Published on 08 Sep 2020
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01649
- 7,377 views
- 38 citations
Original Research
Published on 07 Sep 2020
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01677
- 6,289 views
- 48 citations
Original Research
Published on 02 Sep 2020
Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01645
- 3,430 views
- 11 citations
Original Research
Published on 02 Sep 2020
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01167
- 2,716 views
- 13 citations
Original Research
Published on 02 Sep 2020
A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01503
- 3,362 views
- 2 citations
Original Research
Published on 02 Sep 2020
Developing and Assessing the Effectiveness of a Nurse-Led Home-Based Educational Programme for Managing Breathlessness in Lung Cancer Patients. A Feasibility Study
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01366
- 7,601 views
- 12 citations
Original Research
Published on 25 Aug 2020
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.01455
- 4,795 views
- 15 citations